| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 07.06.2021 og
angivet som gældende fra 04.06.2021 (1071
dage). |
Ingen historik.
| Branche | | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
| Sidst opdateret den 07.06.2021 og
angivet som gældende fra 04.06.2021 (1071
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 14.12.2021 og
angivet som gældende fra 14.12.2021 (878
dage). |
| Historik | Start | Stop |
|---|
| false | 14.12.2021 | |
| true | 04.06.2021 | 13.12.2021 |
Ingen nuværende registrering.
Ingen historik.
| Telefonnummer | | 26343323. |
| Sidst opdateret den 21.12.2021 og
angivet som gældende fra 21.12.2021 (871
dage). |
| Historik | Start | Stop |
|---|
| 26343323 | 21.12.2021 | |
| 41194105 | 04.06.2021 | 20.12.2021 |
| Navne | | Epoqe Pharma ApS. |
| Sidst opdateret den 14.12.2021 og
angivet som gældende fra 14.12.2021 (878
dage). |
| Historik | Start | Stop |
|---|
| Epoqe Pharma ApS | 14.12.2021 | |
| Patentselskabet af 31. maj 2021 ApS | 04.06.2021 | 13.12.2021 |
| Binavne | | Patentselskabet af 31. maj 2021 ApS. |
| Sidst opdateret den 14.12.2021 og
angivet som gældende fra 14.12.2021 (878
dage). |
Ingen historik.
| Tegningsregel | | Selskabet tegnes af hele bestyrelsen i forening, af hele direktionen i forening, eller af bestyrelsens formand i
forening med et direktionsmedlem. |
| Sidst opdateret den 23.10.2023 og
angivet som gældende fra 23.10.2023 (200
dage). |
| Fortolkning
(3 tegningsmuligheder)
| | hele_bestyrelsen + |
| hele_direktionen + |
| formanden + 1 direktionsmedlem |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af hele bestyrelsen i forening, af hele direktionen i forening, eller af bestyrelsens formand i
forening med et direktionsmedlem | 23.10.2023 | |
| Selskabet tegnes af to direktører i forening | 14.12.2021 | 22.10.2023 |
| Selskabet tegnes af en direktør | 04.06.2021 | 13.12.2021 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab
Revisionsvirksomhedens CVR-nr.:14119299
Beskrivelse af revisor:Statsautoriseret revisor
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for Opinion
We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Epoqe Pharma ApS for the financial year 1 July 2022 - 30 June 2023, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes, for the Company. The financial statements are prepared under the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the financial position of the Company at 30 June 2023, and of the results of the Company's operations for the financial year 1 July 2022 - 30 June 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on Management’s Review
Management is responsible for Management’s Review.
Our opinion on the financial statements døs not cover Management’s Review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that Management’s Review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of Management’s Review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration